A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia

Trial Profile

A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs Moxifloxacin; Pomaglumetad methionil
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
    • 11 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 29 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top